Drug intelligence / Profile preview

JNJ-67856633

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Oral

Overview

JNJ-67856633 is a first-in-class, orally bioavailable, small molecule inhibitor of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1). MALT1 is a key component of the CBM (CARD11-BCL10-MALT1) complex, which mediates NF-κB signaling downstream of the B-cell receptor (BCR). By inhibiting the proteolytic activity of MALT1, JNJ-67856633 suppresses the constitutive NF-κB activation often found in B-cell malignancies. It is currently being evaluated in Phase 1 clinical trials for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Other names: MALT1 inhibitor JNJ-67856633MALT-1 inhibitor JNJ-67856633MALT 1 inhibitor JNJ-67856633

Targets

MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1)

Beyond the preview

Go deeper on JNJ-67856633.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-67856633.

Explore the full profile